Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02994446
Other study ID # RD-14-001P
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2016
Est. completion date October 4, 2021

Study information

Verified date April 2022
Source Thermedical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date October 4, 2021
Est. primary completion date April 21, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Patient has recurrent, symptomatic, monomorphic VT 2. Patient has drug refractory or drug intolerant VT following use of at least one Class III antiarrhythmic as demonstrated by a recurrent arrhythmia and is not a suitable candidate per the investigator's expert opinion for ongoing or alternative drug therapy 3. A prior failed ablation as evidenced by ICD device therapy within the prior 6 months. 4. Patient has minimum 3 month ICD interrogation history available for evaluation 5. Patient has LVEF > 20%, confirmed by echo or comparable technique during baseline evaluation 6. Patient is at least 18 years old 7. Patient has signed the informed consent, and is willing and able to participate in all study procedures and follow up requirements Exclusion Criteria 1. Patients with idiopathic VT 2. Patients with VT with ECG or MRI/CT findings suggestive of right ventricular free wall origin findings. 3. Patients with VTs of septal origin may be excluded as such ablations require special care to minimize the risk of heart block, particularly within 2 cm of the AV node/proximal conduction system. Patients requiring ablation at such locations should only be included when the arrhythmia itself is life-threatening or otherwise sufficiently severe to justify the risk. 4. Patient with myocardial infarction (MI) or unstable angina within previous 60 days 5. Patient with cardiac surgery or percutaneous coronary intervention (PCI) within previous 60 days 6. Patient with class IV (NYHA) heart failure 7. Patient with mechanical mitral valve, severe aortic stenosis or flail mitral leaflet 8. Patient with left ventricular assist device planned or required for the procedure 9. Patients with co-morbidities such that they have less than 1 year life expectancy 10. Patient with significant intracardiac and/or laminated thrombus evident by transesophogeal echo (TEE) or transthoracic echo (TTE) (with contrast) within 2 days of the ablation procedure 11. Patient with thrombocytopenia or other coagulopathy 12. Women who are or may potentially be pregnant. (must be post-menopausal or have a negative pregnancy test) 13. Patient with other acute illness or active systemic infection (unrelated to VT or its origin) 14. Significant congenital anomaly heart disease or anomaly 15. Allergy or contraindications to the medications/agents used during a standard ablation/EP intervention. 16. Patient concurrently enrolled in any other investigational drug or device study that the investigator deems would interfere with study results.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Saline-Enhanced Radiofrequency Catheter and Ablation System
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter

Locations

Country Name City State
Canada Montreal Heart Institute - Institut de Cardiologie de Montréal Montréal Quebec
Canada Southlake Regional Health Centre Newmarket Ontario
Canada Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec Québec

Sponsors (1)

Lead Sponsor Collaborator
Thermedical, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serious Adverse Events that are potentially device-related Within 30 days of ablation
Primary Major Adverse Cardiac Events MACE will be accessed from time of ablation to time of discharge from hospital following the ablation (generally within 2 days of ablation procedure). Within 2 days after ablation procedure
Primary Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels At completion of ablation procedure
Secondary Intraprocedural non-inducibility and/or scar homogenization of target VT At completion of ablation procedure
Secondary Elimination of the target VT and/or reduction in number of VT episodes Within first 6 months of ablation procedure
See also
  Status Clinical Trial Phase
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT04075253 - Acute Effect of One Single Bout of High Intensity Exercise on the Tendency for Ventricular Arrhythmia N/A
Completed NCT04070300 - Physical Activity and Ventricular Arrhythmias N/A
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000480 - Multicenter Unsustained Tachycardia Trial (MUSTT) Phase 3
Completed NCT05086510 - Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Recruiting NCT01222156 - Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping Phase 1/Phase 2
Terminated NCT00749671 - Bispectral Index Monitoring During Testing in the Electrophysiology Lab N/A
Recruiting NCT00385749 - Right Ventricular Defibrillation Lead Select Site Study N/A
Completed NCT00382928 - Automatic External Defibrillation Monitoring in Cardiac Arrest Phase 1
Completed NCT00279279 - PREPARE - Primary Prevention Parameters Evaluation N/A
Terminated NCT00776087 - European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) N/A
Withdrawn NCT00510731 - The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events N/A
Completed NCT01572246 - Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators N/A
Completed NCT00170287 - SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD) Phase 4
Completed NCT00147277 - ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Phase 4
Completed NCT00004559 - Fatty Acid Antiarrhythmia Trial (FAAT) Phase 3
Completed NCT00702117 - Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Phase 4
Completed NCT00232297 - Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS Phase 2